Abstract 358: Targeting of Heparin Binding EGF-like Growth Factor (HB-EGF) Efficiently Inhibits Atherosclerosis
Objective: Heparin-binding EGF-like growth factor (HB-EGF) is a receptor ligand that regulates inflammatory gene expression in the human aortic endothelial cells. In this study, we examined the effects of targeting HB-EGF using an antisense oligonucleotide (ASO) in the development of atherosclerosis.
Methods and Results: Control and HB-EGF ASOs were injected intraperitoneally (i.p.; weekly; Dose: 50 mg/kg/wk) for 12 weeks into LDLR deficient mice fed a fat-enriched diet (21% fat; 0.2% cholesterol). Compared with the control ASO injected group (N=13), the HB-EGF ASO injected group (N=15) had efficiently reduced atherosclerosis in the arch of aorta (p<0.0001). The HB-EGF ASO also significantly reduced plasma cholesterol concentration (p = 0.0397). We observed that the VLDL was consistently reduced in all HB-EGF ASO injected mice tested. In liver tissue, the HB-EGF ASO induced significant downregulation of gene expressions of the sterol synthetic pathway as determined by a microarray and DAVID functional analysis (adjusted p = 5.5 x 10-9)). The HB-EGF ASO also induced lipid droplet accumulation in liver tissues as determined by histological analysis with liver tissue sections.
Conclusions: This study indicates that HB-EGF is a key mediator for atherosclerosis and the targeting of HB-EGF is an efficient approach to inhibit lesion formation in the aorta. Downregulation of the sterol synthesis pathway and reduction of VLDL particles in the blood may contribute to the protective effects of HB-EGF ASO.
Author Disclosures: S. Lee: None. R. Lee: None. M. Graham: None. S. Kim: None. L. Yang: None. D. Rateri: None. J.A. Berliner: None. A.J. Lusis: None.
- © 2015 by American Heart Association, Inc.